FloSeal application
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynecologic Cancer
Conditions
Gynecologic Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tubal Cancer
Trial Timeline
Sep 1, 2012 → Nov 1, 2015
NCT ID
NCT01679483About FloSeal application
FloSeal application is a pre-clinical stage product being developed by Baxter for Gynecologic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01679483. Target conditions include Gynecologic Cancer, Cervical Cancer, Endometrial Cancer.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01679483 | Pre-clinical | Completed |
Competing Products
13 competing products in Gynecologic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IMGN151 + Carboplatin + Bevacizumab + Olaparib | AbbVie | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 1 | 33 |
| Atezolizumab + Rucaparib | Roche | Phase 1 | 33 |
| Vigil + Atezolizumab | Roche | Phase 2 | 52 |
| darbepoetin alfa + recombinant human erythropoietin (rHuEPO) | Amgen | Phase 2 | 51 |
| Oral apixaban + Subcutaneous enoxaparin | Bristol Myers Squibb | Phase 2 | 51 |
| AK112 | Akeso | Phase 2 | 51 |
| Ciprofol + Propofol | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Floseal | Baxter | Phase 3 | 74 |
| IPH2201 | Innate Pharma | Phase 1 | 25 |
| Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) | Alaunos Therapeutics | Phase 1/2 | 33 |
| Neoantigen specific TCR-T cell drug product | Alaunos Therapeutics | Pre-clinical | 15 |